Targeted molecular therapies and predictive biomarkers in a novel orthotopic xenograft model of oesophageal carcinoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1056240

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Oesophageal cancer is the most rapidly increasing malignancy in Western society. This disease often presents in advanced stages with poor response to established medical and surgical therapies. Our aim is to develop a novel mouse model of oesophageal cancer, allowing us to tailor cancer-inhibiting molecular treatments to individual patients by predicting therapeutic success or resistance with the use of cellular markers identified in our animal mode.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Postgraduate Scholarships

Funding Amount: $120,253.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

ErbB2-mediated cell signalling | ErbB2-overexpressed cancers | animal model | biomarkers | cancer therapy | epidermal growth factor receptor (EGFR) | gastrointestinal tumourigenesis | molecular oncology | mouse models | oesophageal cancer

Related Links